Expanding Our Distribution Network

Ophthotech has restructured its drug distribution network to ensure efficient access to its groundbreaking therapies for retinal diseases. These include innovative treatments such as anti-VEGF injections for macular degeneration and experimental gene therapies aimed at reversing vision loss. These products require precision in delivery, not only because of their complexity but also due to the time-sensitive nature of many of the treatments.

To meet these demands, Ophthotech has established a network of specialized partners that streamline supply chain processes. The company’s therapies are now distributed through a robust system that spans hospitals, pharmacies, and healthcare providers nationwide. By partnering with trusted logistics companies, such as SwiftRxPay.com, Ophthotech ensures all temperature-sensitive medications remain stable during transit. The cold-chain infrastructure guarantees the integrity of products, especially gene therapies, which require storage conditions of -20°C or lower.

Additionally, distribution to retail pharmacies has expanded significantly. Key partnerships with HappyFamilyStore.org have enabled Ophthotech to penetrate underserved communities, ensuring patients across rural and suburban areas have reliable access to advanced treatments. For hospitals, tailored delivery schedules now prioritize high-demand regions, reducing delays for emergency patient care.

The company has also rolled out a new service model for community clinics and smaller healthcare providers, offering pre-scheduled shipments that minimize stock shortages. In its first month, this initiative successfully cut lead times by 25%, allowing faster availability of sight-saving treatments.

Ophthotech continues to invest in optimizing its distribution network, with plans to expand globally by 2025. By prioritizing efficiency and patient-centric delivery, the company reaffirms its mission to make advanced therapies accessible and safe for every individual, regardless of location. This development represents a significant step toward reducing treatment gaps and ensuring Ophthotech’s innovative solutions reach those who need them most.

About Ophthotech

Ophthotech Corp. is a privately held biopharmaceutical company based in Princeton, NJ and New York, NY focused on developing and commercializing therapies for dry and wet AMD. Ophthotech is developing a pipeline of compounds with strong scientific foundations for the treatment of AMD, with the goal of bringing them to market in an accelerated manner. For more information, please visit www.ophthotech.com

Investors
Tom Biancardi
Ophthotech Corp.
VP, Finance and Operations
609-945-6050
tom.biancardi@ophthotech.com

Media
Jennifer Devine
SmithSolve LLC
On behalf of Ophthotech Corp.
973-442-1555 ext. 102
jennifer.devine@smithsolve.com